Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluation

Detalhes bibliográficos
Autor(a) principal: Freire, Thamires Batello
Data de Publicação: 2019
Outros Autores: Dario, Michelli Ferrera, Mendes, Otávio Gil, Oliveira, Andressa Costa de, Vetore Neto, Alberto, Faria, Dalva Lucia Araújo de, Silva, Vânia Rodrigues Leite e, Baby, André Rolim, Velasco, Maria Valéria Robles
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/164841
Resumo: The Ginoide Hydrolipodystrophy (GHLD), commonly known as cellulite, occurs in 80-90% of the female population after the puberty period and comes from a metabolic modification in the cutaneous adipose tissue. Caffeine has been used in topical formulations due to its lipolytic action. We studied a nanoemulsion (F3) containing caffeine with two surfactants (oleth-3 and oleth-20) by emulsification method by phase inversion temperature inversion (PIT). The polydispersion indices (PDI) showed the reduced deviation of 0.1. The mean droplet size was ~ 40 nm. The evaluated constant of Ostwald, in the refrigerator condition was the most favorable during the stability test. In the In Raman spectroscopy assay, the caffeine bands found in F3 were compatible with those found in the caffeine solution (1337, 652.5 and 558.2 cm-1). There was no interaction of caffeine anhydrous with other ingredients in nanoemulsion. In the in vitro safety assay the result of 1.4 ranked the F3 as slightly irritating. In the natural membrane, cutaneous permeation test (human skin) permeate concentrations did not exceed the saturation concentration of the PBS buffer (48.96 μg/3 mL). The caffeine solution and F3 permeated statistically equal, but the nanoemulsion visually and sensorially improved the caffeine precipitation.
id USP-31_37b5bcfaf921482c05e98a4927d80d77
oai_identifier_str oai:revistas.usp.br:article/164841
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluationCelluliteCaffeineGynoid hydrolipodystrophyNanoemulsionPermeationThe Ginoide Hydrolipodystrophy (GHLD), commonly known as cellulite, occurs in 80-90% of the female population after the puberty period and comes from a metabolic modification in the cutaneous adipose tissue. Caffeine has been used in topical formulations due to its lipolytic action. We studied a nanoemulsion (F3) containing caffeine with two surfactants (oleth-3 and oleth-20) by emulsification method by phase inversion temperature inversion (PIT). The polydispersion indices (PDI) showed the reduced deviation of 0.1. The mean droplet size was ~ 40 nm. The evaluated constant of Ostwald, in the refrigerator condition was the most favorable during the stability test. In the In Raman spectroscopy assay, the caffeine bands found in F3 were compatible with those found in the caffeine solution (1337, 652.5 and 558.2 cm-1). There was no interaction of caffeine anhydrous with other ingredients in nanoemulsion. In the in vitro safety assay the result of 1.4 ranked the F3 as slightly irritating. In the natural membrane, cutaneous permeation test (human skin) permeate concentrations did not exceed the saturation concentration of the PBS buffer (48.96 μg/3 mL). The caffeine solution and F3 permeated statistically equal, but the nanoemulsion visually and sensorially improved the caffeine precipitation.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2019-12-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/16484110.1590/s2175-97902019000218236Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e18236Brazilian Journal of Pharmaceutical Sciences; v. 55 (2019); e18236Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e182362175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/164841/158007Copyright (c) 2019 Brazilian Journal of Pharmaceutical Scienceshttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFreire, Thamires BatelloDario, Michelli FerreraMendes, Otávio GilOliveira, Andressa Costa deVetore Neto, AlbertoFaria, Dalva Lucia Araújo deSilva, Vânia Rodrigues Leite eBaby, André RolimVelasco, Maria Valéria Robles2021-01-11T18:56:44Zoai:revistas.usp.br:article/164841Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2021-01-11T18:56:44Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluation
title Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluation
spellingShingle Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluation
Freire, Thamires Batello
Cellulite
Caffeine
Gynoid hydrolipodystrophy
Nanoemulsion
Permeation
title_short Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluation
title_full Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluation
title_fullStr Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluation
title_full_unstemmed Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluation
title_sort Nanoemulsion containing caffeine for cellulite treatment: characterization and in vitro evaluation
author Freire, Thamires Batello
author_facet Freire, Thamires Batello
Dario, Michelli Ferrera
Mendes, Otávio Gil
Oliveira, Andressa Costa de
Vetore Neto, Alberto
Faria, Dalva Lucia Araújo de
Silva, Vânia Rodrigues Leite e
Baby, André Rolim
Velasco, Maria Valéria Robles
author_role author
author2 Dario, Michelli Ferrera
Mendes, Otávio Gil
Oliveira, Andressa Costa de
Vetore Neto, Alberto
Faria, Dalva Lucia Araújo de
Silva, Vânia Rodrigues Leite e
Baby, André Rolim
Velasco, Maria Valéria Robles
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Freire, Thamires Batello
Dario, Michelli Ferrera
Mendes, Otávio Gil
Oliveira, Andressa Costa de
Vetore Neto, Alberto
Faria, Dalva Lucia Araújo de
Silva, Vânia Rodrigues Leite e
Baby, André Rolim
Velasco, Maria Valéria Robles
dc.subject.por.fl_str_mv Cellulite
Caffeine
Gynoid hydrolipodystrophy
Nanoemulsion
Permeation
topic Cellulite
Caffeine
Gynoid hydrolipodystrophy
Nanoemulsion
Permeation
description The Ginoide Hydrolipodystrophy (GHLD), commonly known as cellulite, occurs in 80-90% of the female population after the puberty period and comes from a metabolic modification in the cutaneous adipose tissue. Caffeine has been used in topical formulations due to its lipolytic action. We studied a nanoemulsion (F3) containing caffeine with two surfactants (oleth-3 and oleth-20) by emulsification method by phase inversion temperature inversion (PIT). The polydispersion indices (PDI) showed the reduced deviation of 0.1. The mean droplet size was ~ 40 nm. The evaluated constant of Ostwald, in the refrigerator condition was the most favorable during the stability test. In the In Raman spectroscopy assay, the caffeine bands found in F3 were compatible with those found in the caffeine solution (1337, 652.5 and 558.2 cm-1). There was no interaction of caffeine anhydrous with other ingredients in nanoemulsion. In the in vitro safety assay the result of 1.4 ranked the F3 as slightly irritating. In the natural membrane, cutaneous permeation test (human skin) permeate concentrations did not exceed the saturation concentration of the PBS buffer (48.96 μg/3 mL). The caffeine solution and F3 permeated statistically equal, but the nanoemulsion visually and sensorially improved the caffeine precipitation.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-06
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/164841
10.1590/s2175-97902019000218236
url https://www.revistas.usp.br/bjps/article/view/164841
identifier_str_mv 10.1590/s2175-97902019000218236
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/164841/158007
dc.rights.driver.fl_str_mv Copyright (c) 2019 Brazilian Journal of Pharmaceutical Sciences
http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Brazilian Journal of Pharmaceutical Sciences
http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e18236
Brazilian Journal of Pharmaceutical Sciences; v. 55 (2019); e18236
Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e18236
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222914525528064